Purchase Order HT942524P0015
Award Date
12/6/23
Potential Completion Date
12/10/26
Potential Value
$1.3M
Federal Agency
Defense Health Agency
Awardee
Eitr Biologics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Eitr Biologics, Inc., a for-profit biotechnology company, was made by the Defense Health Agency (DHA) to develop novel nanotherapeutics for combating viral infections and other biological threats. The $1,864,756.31 firm-fixed-price delivery order contract has an ultimate completion date of September 19, 2025. Eitr Biologics specializes in antibody engineering, nanotherapeutics, and the discovery and production of monoclonal antibodies. This contract is part of a...
This is a $750,000.00 firm fixed price delivery order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc. for the development of novel nanotherapeutic approaches for the treatment of pneumonic plague. The order is part of a larger $4.39 million Indefinite Delivery Vehicle (IDV) contract between Eitr Biologics and DHA to advance the research and development of nanotherapeutics to combat biological threats. The work will be performed in San Diego, California and involves assessing...
This federal contract award to Eitr Biologics, Inc. for $499,896.06 was issued by the Defense Health Agency (DHA) on July 1, 2024. The award is for the development of a novel therapeutic medical countermeasure capable of protecting against pneumonic unencapsulated Yersinia pestis, the causative agent of pneumonic plague. The contract is a Firm Fixed Price Delivery Order with a completion date of June 30, 2025. This award is part of a larger Indefinite Delivery Vehicle (IDV) held by Eitr...
This is a $180,000 fixed-price purchase order awarded by the Defense Health Agency (DHA) to Genovac Antibody Discovery LLC, a small disadvantaged business, to provide human monoclonal antibody (mAb) development services. The contract supports the Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS) and includes performing feasibility studies, developing and producing a panel of fully human mAbs, and shipping the mAbs to AFRIMS...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.5 million firm fixed price definitive contract to HDT Bio Corp. to develop an adaptable RNA-based antibody platform for protection against contemporary and emerging human enteroviruses. The three year contract will support HDT Bio Corp.'s work through June 2025 to create a platform that utilizes RNA-based antibodies to provide protection against various...
The U.S. Defense Health Agency (DHA) has awarded a $76,200 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for adaptive immunosequencing services. The award does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products. The company has previously received awards from the Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) to provide...
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...
This is a $3,247,731 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of a first-in-human therapeutic interfering particle targeting a respiratory virus, under DARPA's research programs. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) by DARPA, with a potential value of $4,579,822, to develop and deliver therapeutic...
This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...
The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,657.20 firm fixed-price purchase order to Ebioscience, Inc., a subsidiary of Affymetrix, Inc., for the supply of monoclonal antibodies, including shipping charges. The contract, which does not have a set-aside designation, was awarded on September 11, 2011, with a completion date of September 19, 2012. This standing order is likely part of NIAID's broader efforts to...